{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:45:55Z","timestamp":1787755555570,"version":"build-2784847793"},"reference-count":51,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T00:00:00Z","timestamp":1658966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Neuromuscular junction disorders (NJDs) are a heterogeneous group of diseases including myasthenia gravis (MG). In some cases, patients are present with myasthenic symptoms without evidence of autoimmune antibodies, making diagnosis challenging. Total plasma exchange (TPE) has proven efficacy in NJDs. The objective is to describe the safety and efficacy of TPE in NJD patients with questionable disease activity or uncertain diagnosis in order to assess the diagnostic potential of TPE. We report an observational, retrospective cohort study of clinical routine data. All the data were derived from the electronic medical records of the Department of Neurology at University Hospital Essen. We searched for patients with NJDs between 1 July 2018 and 30 June 2021. Of the 303 patients who presented to the department with NJDs, 20 were treated with TPE; 9 patients did not show a measurable benefit from TPE (45%), 6 of whom were diagnosed with seronegative MG. Of these, 3 (50%) had long-standing ocular symptoms. There were decreases in the mean arterial pressure, hemoglobin, hematocrit and fibrinogen during treatment, which were not considered clinically relevant. In (seronegative) myasthenic patients, TPE may help to verify an uncertain diagnosis or to reveal possible muscle damage, allowing unnecessary therapy to be avoided.<\/jats:p>","DOI":"10.3390\/jcm11154383","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T20:49:28Z","timestamp":1659041368000},"page":"4383","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Total Plasma Exchange in Neuromuscular Junction Disorders\u2014A Single-Center, Retrospective Analysis of the Efficacy, Safety and Potential Diagnostic Properties in Doubtful Diagnosis"],"prefix":"10.3390","volume":"11","author":[{"given":"Andreas","family":"Totzeck","sequence":"first","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7493-205X","authenticated-orcid":false,"given":"Michael","family":"Jahn","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2774-067X","authenticated-orcid":false,"given":"Benjamin","family":"Stolte","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Thimm","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-3450","authenticated-orcid":false,"given":"Tim","family":"Hagenacker","sequence":"additional","affiliation":[{"name":"Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: A supplement to the Guidelines of the German Neurological Society","volume":"263","author":"Melzer","year":"2016","journal-title":"J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/B978-0-444-63432-0.00024-4","article-title":"Neuromuscular junction disorders","volume":"133","author":"Verschuuren","year":"2016","journal-title":"Handb. Clin. Neurol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1126\/science.1179220","article-title":"Myasthenia gravis: Passive transfer from man to mouse","volume":"190","author":"Toyka","year":"1975","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann. Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1007\/s00415-017-8541-9","article-title":"Lambert-Eaton myasthenic syndrome (LEMS): A rare autoimmune presynaptic disorder often associated with cancer","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1474-4422(21)00463-4","article-title":"Advances and ongoing research in the treatment of autoimmune neuromuscular junction disorders","volume":"21","author":"Verschuuren","year":"2022","journal-title":"Lancet Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-8802-0_25","article-title":"Assessment of Disease Activity, Structural Damage, and Function in Rheumatoid Arthritis","volume":"1868","author":"Hasegawa","year":"2018","journal-title":"Methods Mol. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1002\/acr.20532","article-title":"Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI)","volume":"63","author":"Rider","year":"2011","journal-title":"Arthritis Care Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1744-9987.2009.00684.x","article-title":"Periodic therapeutic plasma exchange in patients with moderate to severe chronic myasthenia gravis non-responsive to immunosuppressive agents: An eight year follow-up","volume":"13","author":"Triantafyllou","year":"2009","journal-title":"Ther. Apher. Dial."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.5603\/AIT.2013.0002","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"Szczeklik","year":"2013","journal-title":"Anaesthesiol. Intensive Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3904","DOI":"10.1007\/s00415-022-11023-z","article-title":"Seronegative myasthenic crisis: A multicenter analysis","volume":"269","author":"Mergenthaler","year":"2022","journal-title":"J. Neurol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/CND.0b013e318275197c","article-title":"Different characteristic phenotypes according to antibody in myasthenia gravis","volume":"14","author":"Oh","year":"2012","journal-title":"J. Clin. Neuromuscul. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1001\/archneur.64.8.1121","article-title":"Classification of myasthenia gravis based on autoantibody status","volume":"64","author":"Suzuki","year":"2007","journal-title":"Arch. Neurol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1749-6632.1998.tb11015.x","article-title":"Reliability testing of the quantitative myasthenia gravis score","volume":"841","author":"Barohn","year":"1998","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_17","first-page":"M597","article-title":"A simple and accurate method for prescribing plasma exchange","volume":"36","author":"Kaplan","year":"1990","journal-title":"ASAIO Trans"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S1567-5688(09)71827-6","article-title":"Plasma exchange and immunoadsorption for autoimmune neurologic diseases\u2014Current guidelines and future perspectives","volume":"10","author":"Klingel","year":"2009","journal-title":"Atheroscler. Suppl."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lipphardt, M., Wallbach, M., and Koziolek, M.J. (2020). Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051597"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/jca.21705","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice\u2014Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue","volume":"34","author":"Padmanabhan","year":"2019","journal-title":"J. Clin. Apher."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Rolfes, L., Pfeuffer, S., Ruck, T., Melzer, N., Pawlitzki, M., Heming, M., Brand, M., Wiendl, H., and Meuth, S.G. (2019). Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs-A Systematic Review. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101623"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1159\/000447059","article-title":"Escalation Therapy of Steroid Refractory Multiple Sclerosis Relapse with Tryptophan Immunoadsorption\u2014Observational Multicenter Study with 147 Patients","volume":"75","author":"Schimrigk","year":"2016","journal-title":"Eur. Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/1744-9987.12820","article-title":"Removal Characteristics of Immunoadsorption with the Tryptophan-Immobilized Column Using Conventional and Selective Plasma Separators in the Treatment of Myasthenia Gravis","volume":"23","author":"Ohkubo","year":"2019","journal-title":"Ther. Apher. Dial."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","article-title":"Burden of disease in myasthenia gravis: Taking the patient\u2019s perspective","volume":"269","author":"Lehnerer","year":"2022","journal-title":"J. Neurol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.25122\/jml-2020-0145","article-title":"The epidemiology of myasthenia gravis","volume":"14","author":"Bubuioc","year":"2021","journal-title":"J. Med. Life"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0140-6736(76)91917-6","article-title":"Remission of myasthenia gravis following plasma-exchange","volume":"2","author":"Pinching","year":"1976","journal-title":"Lancet"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJM197711242972102","article-title":"Plasmapheresis and immunosuppressive drug therapy in myasthenia gravis","volume":"297","author":"Dau","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1212\/WNL.28.3.266","article-title":"Function of circulating antibody to acetylcholine receptor in myasthenia gravis: Investigation by plasma exchange","volume":"28","author":"Pinching","year":"1978","journal-title":"Neurology"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000333845","article-title":"Techniques of extracorporeal cytokine removal: A systematic review of the literature","volume":"33","author":"Atan","year":"2012","journal-title":"Blood Purif."},{"key":"ref_31","first-page":"60","article-title":"Plasmapheresis in clinical medicine","volume":"138","author":"Linker","year":"1983","journal-title":"West. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000334155","article-title":"Plasmapheresis in immunologic renal disease","volume":"33","author":"Pusey","year":"2012","journal-title":"Blood Purif."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis. Myasthenia Gravis Clinical Study Group","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann. Neurol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"662856","DOI":"10.3389\/fneur.2021.662856","article-title":"Therapeutic Plasma Exchange in Myasthenia Gravis: A Systematic Literature Review and Meta-Analysis of Comparative Evidence","volume":"12","author":"Ipe","year":"2021","journal-title":"Front. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1177\/1756285616637046","article-title":"Immunoadsorption versus plasma exchange versus combination for treatment of myasthenic deterioration","volume":"9","author":"Krenzer","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1002\/mus.23626","article-title":"Safety of plasma exchange therapy in patients with myasthenia gravis","volume":"47","author":"Ebadi","year":"2013","journal-title":"Muscle Nerve"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis. Prevalence, clinical correlates, and diagnostic value","volume":"26","author":"Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/mus.27341","article-title":"Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis","volume":"64","author":"Ching","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s42466-021-00129-w","article-title":"Simultaneous paraneoplastic cerebellar degeneration, Lambert-Eaton syndrome and neuropathy associated with AGNA\/anti-SOX1 and VGCC antibodies","volume":"3","author":"Feldheim","year":"2021","journal-title":"Neurol. Res. Pract."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1001\/archneur.63.8.1066","article-title":"Plasma exchange in neuroimmunological disorders: Part 2. Treatment of neuromuscular disorders","volume":"63","author":"Lehmann","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1001\/jamaneurol.2016.2277","article-title":"Seronegative Myasthenia Gravis-A Vanishing Disorder?","volume":"73","author":"Kaminski","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1093\/brain\/awn131","article-title":"\u2018Seronegative\u2019 myasthenia gravis is no longer seronegative","volume":"131","author":"Lindstrom","year":"2008","journal-title":"Brain"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1136\/jnnp.36.2.244","article-title":"Neurogenic muscle involvement in myasthenia gravis. A clinical and histopathological study","volume":"36","author":"Oosterhuis","year":"1973","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/path.1700650202","article-title":"Histological changes in the striped muscles in myasthenia gravis","volume":"65","author":"Russell","year":"1953","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nmd.2019.03.009","article-title":"A review of the histopathological findings in myasthenia gravis: Clues to the pathogenesis of treatment-resistance in extraocular muscles","volume":"29","author":"Europa","year":"2019","journal-title":"Neuromuscul. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1097\/WNO.0000000000000534","article-title":"Extraocular Muscle Findings in Myasthenia Gravis Associated Treatment-Resistant Ophthalmoplegia","volume":"37","author":"Rautenbach","year":"2017","journal-title":"J. Neuro-Ophthalmol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): A phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jcrc.2021.05.023","article-title":"Definition and incidence of hypotension in intensive care unit patients, an international survey of the European Society of Intensive Care Medicine","volume":"65","author":"Schenk","year":"2021","journal-title":"J. Crit. Care"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1525-1594.1986.tb02515.x","article-title":"Membrane plasma separation through small-area, hollow-fiber filters","volume":"10","author":"Gupta","year":"1986","journal-title":"Artif. Organs"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1046\/j.1526-0968.2001.00316.x","article-title":"Membrane plasmapheresis in the United States: A review over the last 20 years","volume":"5","author":"Siami","year":"2001","journal-title":"Ther. Apher."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/ene.13264","article-title":"Early platelet and leukocyte decline in patients with neuroinflammatory disorders after intravenous immunoglobulins","volume":"24","author":"Totzeck","year":"2017","journal-title":"Eur. J. Neurol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4383\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:58:05Z","timestamp":1760140685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/15\/4383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,28]]},"references-count":51,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["jcm11154383"],"URL":"https:\/\/doi.org\/10.3390\/jcm11154383","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,28]]}}}